Itani Taha, Jacobsen Kathryn H, Nguyen Tim, Wiktor Stefan Z
Global Hepatitis Programme, HIV/AIDS Department, World Health Organization, Geneva, Switzerland; Department of Public Health Medicine, School of Public Health, Bielefeld University, Bielefeld, Germany.
Department of Global & Community Health, George Mason University, Fairfax, Virginia, USA.
Vaccine. 2014 Oct 21;32(46):6067-74. doi: 10.1016/j.vaccine.2014.09.006. Epub 2014 Sep 16.
Few country-level estimates for hepatitis A virus (HAV) seroprevlance are available for the 23 countries in the Eastern Mediterranean region (EMRO) of the World Health Organization.
We used a three-stage approach to assign an HAV endemicity level to each country in North Africa and the Middle East based on the age at midpoint of population immunity. First, we conducted a systematic review to identify all age-seroprevalence studies conducted within the past 10 years. Second, for countries without first-stage evidence we searched for incidence data and older seroprevalence data. Third, for countries with no hepatitis A data, we estimated HAV endemicity based on socioeconomic and water indicators.
This three-stage method allowed us to estimate country-specific endemicity levels for every country in EMRO even though first-stage evidence was only available for nine countries and for three countries only third-stage evidence was available. The region has a heterogeneous hepatitis A risk profile, with 13 countries having very high endemicity (an age at midpoint of population immunity in early childhood), three having high endemicity (late childhood), and seven having intermediate endemicity (early adulthood).
The three-stage estimation approach enables the creation of a complete country-level map of HAV risk in EMRO. Given the heterogeneity of HAV endemicity levels in the region and the likelihood of transitions to lower incidence rates and greater adult susceptibility in the near future, enhanced surveillance for hepatitis A would strengthen decisions about vaccination policy in the region.
世界卫生组织东地中海区域(EMRO)的23个国家中,关于甲型肝炎病毒(HAV)血清流行率的国家级估计数据很少。
我们采用三阶段方法,根据人群免疫中点年龄为北非和中东的每个国家确定甲型肝炎的流行程度。首先,我们进行了系统综述,以确定过去10年内开展的所有年龄血清流行率研究。其次,对于没有第一阶段证据的国家,我们搜索发病率数据和更早期的血清流行率数据。第三,对于没有甲型肝炎数据的国家,我们根据社会经济和水指标估计甲型肝炎的流行程度。
这种三阶段方法使我们能够估计EMRO每个国家的特定国家流行程度,尽管仅9个国家有第一阶段证据,仅3个国家有第三阶段证据。该区域甲型肝炎风险状况各异,13个国家流行程度非常高(人群免疫中点年龄在幼儿期),3个国家流行程度高(儿童晚期),7个国家流行程度中等(成年早期)。
三阶段估计方法能够绘制出EMRO完整的国家层面甲型肝炎风险地图。鉴于该区域甲型肝炎流行程度的异质性以及近期发病率可能下降和成人易感性增加的情况,加强甲型肝炎监测将有助于完善该区域的疫苗接种政策决策。